Stay engaged in the latest updates on immuno-oncology in breast cancer, bladder cancer, head and neck cancer, lung cancer, and melanoma with this virtual grand rounds series. Each month you can participate in a new live broadcast featuring an expert speaking on recent updates and key findings in immuno-oncology. You can access these webinars through your desktop computer, iPhone, iPad, and Android devices. Don’t miss out on this exciting series.
1.0 AMA PRA Category 1 Credit™
Jean-Pascal Machiels, MD, PhDCliniques universitaires Saint-Luc
Université catholique de Louvain
Solange Peters, MD, PhDUniversity of Lausanne
Thomas Powles, MBBS, MRCP, MDBarts Cancer Institute
Queen Mary University of London
London, United Kingdom
Peter Schmid, MD, PhD, FRCPQueen Mary University of London
London, United Kingdom
This educational activity is designed to meet the needs of medical oncologists and other healthcare professionals involved in the treatment of patients with breast cancer, bladder cancer, head and neck cancer, lung cancer, and melanoma.
After successful completion of this educational activity, participants should be able to:
- Discuss the rationale for using immune checkpoint inhibitors, alone and in combination with other novel agents, for the treatment of solid tumors
- Formulate optimal treatment plans that use immune checkpoint inhibitors for the treatment of solid tumors
- Analyze clinical trial data evaluating the efficacy and safety of immune checkpoint inhibitors for the management of solid tumors
- Develop treatment plans to manage immune-related adverse events associated with immune checkpoint inhibitors
This educational activity is supported by a grant from Merck Sharp and Dohme Corp.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.